Shopping Cart 0
Cart Subtotal
USD 0

Merck KGaA (MRK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, OLED materials and cosmetic active ingredients. The company also provides a wide range of products including lab water systems to gene editing tools, cell lines, antibodies and end-to-end systems. Merck serves healthcare, performance materials and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

Merck KGaA (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 9

List of Figures 12

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16

Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18

Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19

Merck KGaA, Pharmaceuticals & Healthcare, Deal Details 28

Asset Purchase 28

Merck KgaA Acquires SevenSeas Original Brand 28

Venture Financing 29

Sutro Biopharma Raises USD85.4 Million in Series E Financing 29

SerImmune Raises USD8 Million in Venture Financing 31

TocopheRx Raises USD 3.3 Million In Seed Financing 32

Partnerships 33

Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 33

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 34

Accelerated Cure Project Enters into Co-Development Agreement with EMD Serono 35

Immutep Enters into Agreement with Merck and Pfizer 36

Checkmate Pharma Enters into Partnership with Merck and Pfizer 37

Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 38

Vyriad Enters into Collaboration Agreement with Merck and Pfizer 39

Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 40

Merck Enters into Development Agreement with SFJ Pharma 41

Forty Seven Enters into Agreement with Merck 42

Merck Enters into Agreement with Avanti Lipids Polar 43

Neon Therapeutics Enters into Agreement with Merck 44

Orexigen Therapeutics Enters into Agreement with Merck KGaA 45

MilliporeSigma to Enter into Agreement with Samsung Biologics 46

Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 47

MilliporeSigma Enters into Agreement with Angiex 48

Merck Enters into Partnership with Angiex 49

Millipore Enter into Partnership with Baylor College of Medicine and Texas Children's Hospital 50

Acino International Enters into Distribution Agreement with Merck 51

Cancer Research Technology Enters into Agreement with Merck 52

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 53

SerImmune Enters into R&D Agreement with Merck 54

Human Longevity Enters into Agreement with Merck 55

F-star Biotech Enters into Partnership with Merck 56

EpiThany Enters into Agreement with Merck and Pfizer 57

VAXIMM Enters into Agreement with Merck and Pfizer 58

Avillion Enters into Co-Development Agreement with Merck 59

Merck Enters into Agreement with Palantir Technologies 60

EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 61

F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 62

Evotec Partners with Merck 63

BioMed X Enters into Agreement with Merck 64

Debiopharm Partners with Merck and Pfizer 65

Transgene Enters into Agreement with Merck and Pfizer 66

Vaccinex Enters into Agreement with Merck 67

PCAS Enters into Distribution Agreement with MilliporeSigma 68

MilliporeSigma Enters into Research Agreement with International Vaccine Institute 69

Selvita Enters into Agreement with Merck 70

Merck Enters into Agreement with University of Buea 71

Merck, Pfizer and Verastem Enter into Agreement 72

Merck Enters into Research Agreement with European Molecular Biology Labs 73

Merck, Pfizer and Syndax Pharma Enter into Agreement 74

Selvita Enters into Development and Commercialization Agreement with Merck 75

Biothera Pharma Expands Agreement with Merck 76

Sigma-Aldrich Enters into Agreement with Sanger Institute 77

Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 78

Nippon Shinyaku Enters into Co-Promotion Agreement with Merck Serono 79

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 80

Aeterna Zentaris Enters into Agreement with EMD Serono 81

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 82

Lucigen Enters into Distribution Agreement with Sigma-Aldrich 83

Merck Serono Enters into Co-Development Agreement with MMV 84

Sigma-Aldrich Enters into Distribution Agreement with Roche 85

Merck Enters into Development Agreement with Precision Biologics 86

Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 87

Pfizer Enters into Co-Development Agreement with Merck 88

BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 90

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 91

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 92

Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 93

Lupin Enters into Co-Development Agreement with Merck Serono 94

Merck Serono Extends R&D Agreement with San Raffaele 95

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 96

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 97

Bionovis Enters into Agreement with Merck 98

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 99

EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 100

KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 101

Biopharm Enters Into Research Agreement With Merck Serono 102

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 103

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 104

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 105

Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 106

Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 107

Isu Abxis Enters into Co-Development Agreement with Merck 108

Luminex Extends Distribution Agreement With EMD Millipore 109

Alchemia Enters Into Collaboration Agreement with Merck Serono 110

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 111

Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 112

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 113

Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 114

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 115

EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 116

AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 117

EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 118

Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 119

Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 120

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 121

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 122

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 124

Genovis Enters Into Distribution Agreement With Sigma-Aldrich 125

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 126

EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 127

EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 128

Mapi Pharma Amends Co-Development Agreement With Merck 129

TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 130

Licensing Agreements 131

Isotopen Enters into Option Agreement to License for Folate Receptor with Merck 131

Merck Enters into Licensing Agreement with Nerviano Medical Sciences 132

Selexis Enters into Licensing Agreement with Merck KGaA 133

Merck Enters into Licensing Agreement with Domain Therapeutics 134

Merck Enters into Licensing Agreement with Vertex Pharma 135

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 136

ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 137

EMD Millipore Enters into Licensing Agreement with Singulex 138

Intrexon Enters into Licensing Agreement with Merck Serono 139

Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 140

EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 141

MorphoSys Enters into Licensing Agreement with Merck Serono 142

Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 143

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 144

ObsEva Enters Into Licensing Agreement With Merck Serono 145

Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 146

Merck Enters into Licensing Agreement with Weizmann Institute of Science 147

Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 148

Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 149

EMD Serono Enters into Licensing Agreement with Sutro Biopharma 150

Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 151

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 152

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 153

Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 155

Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 156

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 157

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 158

EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 159

Materia Extends Licensing Agreement With Sigma Aldrich 160

PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 161

Ligand Pharma Enters Into Licencing Agreement With Merck 162

Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 163

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 164

Sigma Life Science Enters Into Licensing Agreement With Kyoto University 165

Equity Offering 166

KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 166

iOnctura Spin Out from Merck and Cancer Research Technology 167

Debt Offering 168

Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 168

Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 169

Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 170

Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 171

Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 172

Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 173

Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 174

Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 175

Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 176

Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 177

Asset Transactions 178

Procter & Gamble Receives Approval to Acquire 51.8% Stake in Consumer Health Business from Merck for USD4.2 Billion 178

Fresenius Acquires Biosimilars Business from Merck for USD703 Million 180

Zydus Healthcare Acquires Six Brands from Merck 181

Martin Dow Acquires Merck Operations in Pakistan 182

Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 183

Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 185

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 186

Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 187

Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 188

Acquisition 189

Merck Sante Sells 4.74% Stake in Poxel 189

Merck to Acquire Natrix Separations 190

Merck Sells Bangalore Genei for USD1.5 Million 191

Merck Acquires Sigma-Aldrich for USD17 Billion 192

Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 194

Merck And BASF Acquire Majority Stake In Innovation Lab 195

Albany Molecular Research Acquires Cedarburg Pharmaceuticals 196

EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 198

Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 199

Proxy Labs Acquires MicroSafe Laboratories From Millipore 200

Merck KGaA - Key Competitors 201

Merck KGaA - Key Employees 202

Merck KGaA - Locations And Subsidiaries 203

Head Office 203

Other Locations & Subsidiaries 203

Recent Developments 213

Strategy And Business Planning 213

Oct 17, 2018: Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt 213

Jun 05, 2018: Merck Brings Biotechs Closer to Drug Therapy Production and Commercialization 214

Oct 11, 2017: Merck Opens New Life Science Center for Scientific Collaboration 215

Oct 11, 2017: MilliporeSigma Opens New Life Science Center in Massachusetts for Scientific Collaboration 216

Sep 28, 2017: Merck On Course To Achieve Objectives for 2018 217

Sep 22, 2017: Merck Opens China's First BioReliance End-to-End Biodevelopment Center in Shanghai 219

Sep 13, 2017: Merck Expands Celonic's Upstream Capabilities with Mobius Single-use Bioreactors 220

Sep 05, 2017: Merck Prepares Strategic Options for the Consumer Health Business 221

Jun 29, 2017: Merck Expands Packaging Capacity at Swiss Biotech Manufacturing Site of Aubonne 222

Jun 20, 2017: Merck Ventures Creates New Immuno-Oncology Company iOnctura 223

May 16, 2017: Merck: Optimizing the Further Development of the Darmstadt Site 224

May 12, 2017: Merck Opens First Joint Bioprocess Scale-up Lab with Stelis Biopharma in India 225

Apr 20, 2017: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius Bioreactors 226

Jan 10, 2017: Merck Expands End-to-End Biodevelopment Centers in North America, China and Europe 227

Financial Announcements 228

Feb 02, 2018: Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results 228

Nov 09, 2017: Merck Confirms Outlook for 2017 Despite a Challenging Third Quarter 233

Aug 03, 2017: Q2 2017: Merck Sets Course for Future Growth 235

May 18, 2017: Merck Continues to Grow Profitably in the First Quarter 237

Corporate Communications 239

Jan 26, 2018: Merck Appoints Dirk Toepfer as Chief Information Officer 239

Dec 15, 2017: Petra Wicklandt Appointed Head of Corporate Affairs at Merck 240

Dec 12, 2017: Allan Gabor Takes Over the Leadership of Merck in China 241

Dec 06, 2017: Merck: Resignation of Managing Director 242

Aug 03, 2017: Executive Board Changes at Merck 243

Legal and Regulatory 244

Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL 244

Apr 19, 2017: Merck Earns Accreditation for Quality Control of Culture Media 245

Government and Public Interest 246

Jun 12, 2018: Merck Drives Thought Leadership in Ethical Gene Editing 246

Mar 19, 2018: The Pistoia Alliance Calls for Greater Life Sciences Collaboration to Build the Lab of the Future' 247

Nov 10, 2017: Merck Announced as 2017 "Simply the Best Award" Honoree at the Bonnie J. Addario Lung Cancer Foundation's "Simply the Best" Dinner and Gala 248

Oct 26, 2017: Merck Announces Recipients of 1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017 249

Sep 18, 2017: Merck Announces Recipients of the Grant for Growth Innovation 2017 250

Sep 10, 2017: Merck Grant for Oncology Innovation' awards recognize recipients for pushing boundaries in oncology research 251

Jul 06, 2017: Merck Biopharma Innovation Cup 2017 252

Jul 05, 2017: Merck Awards 1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation 253

Jul 05, 2017: Merck KGaA, Darmstadt, Germany Awards 1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation 254

Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 255

Product News 256

Nov 13, 2017: Merck Introduces Stericup Quick Release System for Improved Cell Culture Filtration 256

Oct 30, 2017: Merck: Product Announcement: Process Solutions 257

10/20/2017: Merck Presents New Clinical Data on Evobrutinib at 2017 ACR/ARHP Annual Meeting 258

10/18/2017: Merck to Present New Data on Evobrutinib at ECTRIMS 2017 260

Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 262

Sep 20, 2017: Merck Introduces Eshmuno P Anti-A and Anti-B Chromatography Resins for Enhancement of Plasma-Derived Immunoglobulin 264

06/23/2017: Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis 265

Jun 08, 2017: BioMed X and Merck launch two new crowdsourcing projects in the fields of cancer research and biologics manufacturing 266

05/22/2017: Novel Nanobody To Start Clinical Development In Osteoarthritis Ablynx To Receive 15 Million Milestone Payment 267

May 17, 2017: Merck Develops Alternative CRISPR Genome Editing Method 268

May 15, 2017: Merck Launches Industry's First Off-the-Shelf Cell Culture Media for Perfusion Processes 269

04/28/2017: Investigational Cladribine Tablets Data Show Greater Treatment Effect in Relapsing MS Patients at a Higher Risk of Disease Progression 270

Apr 27, 2018: Merck Advances Cell Analysis with New Benchtop Flow Cytometer with Camera Detection 271

04/21/2017: Merck to Present Data on Cladribine at AAN 2017 272

Apr 03, 2017: Merck Wins Scotland's Life Science Award for Excellence in Community Engagement 275

Mar 06, 2017: Merck Advances Lab Water Purification Technology with Milli-Q(R) IQ 7000 System 276

Feb 13, 2018: Merck Launches Viresolve Barrier Capsule Filters to Protect Against Bioreactor Contamination 277

Clinical Trials 278

Jun 04, 2018: Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018 278

May 16, 2018: Merck to Present M7824 Data at ASCO 2018 280

Apr 17, 2018: Merck to Present Data for Osteoarthritis Drug Candidate M1673 at OARSI 2018 World Congress 281

Apr 17, 2018: Merck to Present Data on its ADAMTS-5 inhibiting nanobody M6495 at OARSI 2018 World Congress 283

Apr 17, 2018: Merck to Present on Sprifermin at OARSI 2018 World Congress 285

Jan 16, 2018: Merck Presents Data on Bifunctional Immunotherapy M7824 at ASCO 2018 Gastrointestinal Cancers Symposium 287

Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification 289

Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting 290

Sep 12, 2017: Merck Advances Immunology Pipeline with Evobrutinib (Brutons Tyrosine Kinase Inhibitor) 292

Jun 26, 2017: Data Provide Additional Insight into the Mode of Action of MAVENCLAD (Cladribine Tablets) in Patients with Relapsing MS 293

Feb 09, 2017: Cladribine Tablets Significantly Reduced Brain Atrophy in Patients with Multiple Sclerosis 294

Other Significant Developments 295

Aug 06, 2018: Merck Foundation Continues to Strengthen Their Merck Cancer Access Program in Gambia, Lesotho, Botswana and Zimbabwe 295

Feb 21, 2018: Merck Invests Additional 40 Million to Enhance Manufacturing and Distribution in Asia 296

Dec 11, 2017: Merck Signs Distribution Agreement with Avanti Polar Lipids 297

Oct 03, 2017: Merck Invests 35 Million in its Italian Biotech Manufacturing Site of Bari 298

Sep 27, 2017: Merck Provides Update on EU's Horizon 2020 Program to Improve Biopharmaceutical Downstream Processing 299

Jul 12, 2017: Merck Refines Western European Life Science Production Site Network 300

Mar 21, 2017: Merck Introduces Mobius MyWay Portfolio for Customized Single-Use Assemblies 301

Mar 21, 2017: Merck Accelerator Hits New Peak of Applications 302

Mar 09, 2017: Merck Generates Record Sales and Continues to Grow Profitably in 2016 303

Feb 15, 2017: Merck to Supply Single-use Systems to WuXi Biologics for Non-GMP Pilot Plant in Shanghai 305

Jan 18, 2017: Merck Launches First Commercial Screening Service to Predict Multiple Sources of DNA Damage 306

Appendix 307

Methodology 307

About GlobalData 307

Contact Us 307

Disclaimer 307


List Of Figure

List of Figures

Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16

Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18


List Of Table

List of Tables

Merck KGaA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Merck KGaA, Deals By Therapy Area, 2012 to YTD 2018 16

Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18

Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19

Merck KgaA Acquires SevenSeas Original Brand 28

Sutro Biopharma Raises USD85.4 Million in Series E Financing 29

SerImmune Raises USD8 Million in Venture Financing 31

TocopheRx Raises USD 3.3 Million In Seed Financing 32

Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 33

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 34

Accelerated Cure Project Enters into Co-Development Agreement with EMD Serono 35

Immutep Enters into Agreement with Merck and Pfizer 36

Checkmate Pharma Enters into Partnership with Merck and Pfizer 37

Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 38

Vyriad Enters into Collaboration Agreement with Merck and Pfizer 39

Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 40

Merck Enters into Development Agreement with SFJ Pharma 41

Forty Seven Enters into Agreement with Merck 42

Merck Enters into Agreement with Avanti Lipids Polar 43

Neon Therapeutics Enters into Agreement with Merck 44

Orexigen Therapeutics Enters into Agreement with Merck KGaA 45

MilliporeSigma to Enter into Agreement with Samsung Biologics 46

Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 47

MilliporeSigma Enters into Agreement with Angiex 48

Merck Enters into Partnership with Angiex 49

Millipore Enter into Partnership with Baylor College of Medicine and Texas Children's Hospital 50

Acino International Enters into Distribution Agreement with Merck 51

Cancer Research Technology Enters into Agreement with Merck 52

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 53

SerImmune Enters into R&D Agreement with Merck 54

Human Longevity Enters into Agreement with Merck 55

F-star Biotech Enters into Partnership with Merck 56

EpiThany Enters into Agreement with Merck and Pfizer 57

VAXIMM Enters into Agreement with Merck and Pfizer 58

Avillion Enters into Co-Development Agreement with Merck 59

Merck Enters into Agreement with Palantir Technologies 60

EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 61

F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 62

Evotec Partners with Merck 63

BioMed X Enters into Agreement with Merck 64

Debiopharm Partners with Merck and Pfizer 65

Transgene Enters into Agreement with Merck and Pfizer 66

Vaccinex Enters into Agreement with Merck 67

PCAS Enters into Distribution Agreement with MilliporeSigma 68

MilliporeSigma Enters into Research Agreement with International Vaccine Institute 69

Selvita Enters into Agreement with Merck 70

Merck Enters into Agreement with University of Buea 71

Merck, Pfizer and Verastem Enter into Agreement 72

Merck Enters into Research Agreement with European Molecular Biology Labs 73

Merck, Pfizer and Syndax Pharma Enter into Agreement 74

Selvita Enters into Development and Commercialization Agreement with Merck 75

Biothera Pharma Expands Agreement with Merck 76

Sigma-Aldrich Enters into Agreement with Sanger Institute 77

Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 78

Nippon Shinyaku Enters into Co-Promotion Agreement with Merck Serono 79

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 80

Aeterna Zentaris Enters into Agreement with EMD Serono 81

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 82

Lucigen Enters into Distribution Agreement with Sigma-Aldrich 83

Merck Serono Enters into Co-Development Agreement with MMV 84

Sigma-Aldrich Enters into Distribution Agreement with Roche 85

Merck Enters into Development Agreement with Precision Biologics 86

Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 87

Pfizer Enters into Co-Development Agreement with Merck 88

BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 90

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 91

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 92

Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 93

Lupin Enters into Co-Development Agreement with Merck Serono 94

Merck Serono Extends R&D Agreement with San Raffaele 95

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 96

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 97

Bionovis Enters into Agreement with Merck 98

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 99

EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 100

KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 101

Biopharm Enters Into Research Agreement With Merck Serono 102

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 103

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 104

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 105

Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 106

Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 107

Isu Abxis Enters into Co-Development Agreement with Merck 108

Luminex Extends Distribution Agreement With EMD Millipore 109

Alchemia Enters Into Collaboration Agreement with Merck Serono 110

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 111

Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 112

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 113

Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 114

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 115

EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 116

AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 117

EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 118

Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 119

Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 120

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 121

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 122

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 124

Genovis Enters Into Distribution Agreement With Sigma-Aldrich 125

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 126

EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 127

EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 128

Mapi Pharma Amends Co-Development Agreement With Merck 129

TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 130

Isotopen Enters into Option Agreement to License for Folate Receptor with Merck 131

Merck Enters into Licensing Agreement with Nerviano Medical Sciences 132

Selexis Enters into Licensing Agreement with Merck KGaA 133

Merck Enters into Licensing Agreement with Domain Therapeutics 134

Merck Enters into Licensing Agreement with Vertex Pharma 135

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 136

ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 137

EMD Millipore Enters into Licensing Agreement with Singulex 138

Intrexon Enters into Licensing Agreement with Merck Serono 139

Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 140

EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 141

MorphoSys Enters into Licensing Agreement with Merck Serono 142

Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 143

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 144

ObsEva Enters Into Licensing Agreement With Merck Serono 145

Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 146

Merck Enters into Licensing Agreement with Weizmann Institute of Science 147

Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 148

Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 149

EMD Serono Enters into Licensing Agreement with Sutro Biopharma 150

Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 151

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 152

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 153

Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 155

Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 156

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 157

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 158

EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 159

Materia Extends Licensing Agreement With Sigma Aldrich 160

PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 161

Ligand Pharma Enters Into Licencing Agreement With Merck 162

Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 163

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 164

Sigma Life Science Enters Into Licensing Agreement With Kyoto University 165

KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 166

iOnctura Spin Out from Merck and Cancer Research Technology 167

Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 168

Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 169

Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 170

Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 171

Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 172

Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 173

Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 174

Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 175

Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 176

Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 177

Procter & Gamble Receives Approval to Acquire 51.8% Stake in Consumer Health Business from Merck for USD4.2 Billion 178

Fresenius Acquires Biosimilars Business from Merck for USD703 Million 180

Zydus Healthcare Acquires Six Brands from Merck 181

Martin Dow Acquires Merck Operations in Pakistan 182

Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 183

Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 185

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 186

Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 187

Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 188

Merck Sante Sells 4.74% Stake in Poxel 189

Merck to Acquire Natrix Separations 190

Merck Sells Bangalore Genei for USD1.5 Million 191

Merck Acquires Sigma-Aldrich for USD17 Billion 192

Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 194

Merck And BASF Acquire Majority Stake In Innovation Lab 195

Albany Molecular Research Acquires Cedarburg Pharmaceuticals 196

EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 198

Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 199

Proxy Labs Acquires MicroSafe Laboratories From Millipore 200

Merck KGaA, Key Competitors 201

Merck KGaA, Key Employees 202

Merck KGaA, Subsidiaries 203

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Merck KGaA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, OLED materials and cosmetic active ingredients. The company also provides a wide range of products including lab water systems to gene editing tools, cell lines, antibodies and end-to-end systems. Merck serves healthcare, performance materials and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

Merck KGaA (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 9

List of Figures 12

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16

Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18

Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19

Merck KGaA, Pharmaceuticals & Healthcare, Deal Details 28

Asset Purchase 28

Merck KgaA Acquires SevenSeas Original Brand 28

Venture Financing 29

Sutro Biopharma Raises USD85.4 Million in Series E Financing 29

SerImmune Raises USD8 Million in Venture Financing 31

TocopheRx Raises USD 3.3 Million In Seed Financing 32

Partnerships 33

Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 33

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 34

Accelerated Cure Project Enters into Co-Development Agreement with EMD Serono 35

Immutep Enters into Agreement with Merck and Pfizer 36

Checkmate Pharma Enters into Partnership with Merck and Pfizer 37

Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 38

Vyriad Enters into Collaboration Agreement with Merck and Pfizer 39

Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 40

Merck Enters into Development Agreement with SFJ Pharma 41

Forty Seven Enters into Agreement with Merck 42

Merck Enters into Agreement with Avanti Lipids Polar 43

Neon Therapeutics Enters into Agreement with Merck 44

Orexigen Therapeutics Enters into Agreement with Merck KGaA 45

MilliporeSigma to Enter into Agreement with Samsung Biologics 46

Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 47

MilliporeSigma Enters into Agreement with Angiex 48

Merck Enters into Partnership with Angiex 49

Millipore Enter into Partnership with Baylor College of Medicine and Texas Children's Hospital 50

Acino International Enters into Distribution Agreement with Merck 51

Cancer Research Technology Enters into Agreement with Merck 52

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 53

SerImmune Enters into R&D Agreement with Merck 54

Human Longevity Enters into Agreement with Merck 55

F-star Biotech Enters into Partnership with Merck 56

EpiThany Enters into Agreement with Merck and Pfizer 57

VAXIMM Enters into Agreement with Merck and Pfizer 58

Avillion Enters into Co-Development Agreement with Merck 59

Merck Enters into Agreement with Palantir Technologies 60

EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 61

F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 62

Evotec Partners with Merck 63

BioMed X Enters into Agreement with Merck 64

Debiopharm Partners with Merck and Pfizer 65

Transgene Enters into Agreement with Merck and Pfizer 66

Vaccinex Enters into Agreement with Merck 67

PCAS Enters into Distribution Agreement with MilliporeSigma 68

MilliporeSigma Enters into Research Agreement with International Vaccine Institute 69

Selvita Enters into Agreement with Merck 70

Merck Enters into Agreement with University of Buea 71

Merck, Pfizer and Verastem Enter into Agreement 72

Merck Enters into Research Agreement with European Molecular Biology Labs 73

Merck, Pfizer and Syndax Pharma Enter into Agreement 74

Selvita Enters into Development and Commercialization Agreement with Merck 75

Biothera Pharma Expands Agreement with Merck 76

Sigma-Aldrich Enters into Agreement with Sanger Institute 77

Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 78

Nippon Shinyaku Enters into Co-Promotion Agreement with Merck Serono 79

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 80

Aeterna Zentaris Enters into Agreement with EMD Serono 81

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 82

Lucigen Enters into Distribution Agreement with Sigma-Aldrich 83

Merck Serono Enters into Co-Development Agreement with MMV 84

Sigma-Aldrich Enters into Distribution Agreement with Roche 85

Merck Enters into Development Agreement with Precision Biologics 86

Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 87

Pfizer Enters into Co-Development Agreement with Merck 88

BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 90

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 91

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 92

Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 93

Lupin Enters into Co-Development Agreement with Merck Serono 94

Merck Serono Extends R&D Agreement with San Raffaele 95

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 96

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 97

Bionovis Enters into Agreement with Merck 98

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 99

EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 100

KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 101

Biopharm Enters Into Research Agreement With Merck Serono 102

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 103

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 104

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 105

Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 106

Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 107

Isu Abxis Enters into Co-Development Agreement with Merck 108

Luminex Extends Distribution Agreement With EMD Millipore 109

Alchemia Enters Into Collaboration Agreement with Merck Serono 110

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 111

Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 112

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 113

Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 114

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 115

EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 116

AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 117

EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 118

Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 119

Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 120

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 121

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 122

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 124

Genovis Enters Into Distribution Agreement With Sigma-Aldrich 125

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 126

EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 127

EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 128

Mapi Pharma Amends Co-Development Agreement With Merck 129

TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 130

Licensing Agreements 131

Isotopen Enters into Option Agreement to License for Folate Receptor with Merck 131

Merck Enters into Licensing Agreement with Nerviano Medical Sciences 132

Selexis Enters into Licensing Agreement with Merck KGaA 133

Merck Enters into Licensing Agreement with Domain Therapeutics 134

Merck Enters into Licensing Agreement with Vertex Pharma 135

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 136

ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 137

EMD Millipore Enters into Licensing Agreement with Singulex 138

Intrexon Enters into Licensing Agreement with Merck Serono 139

Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 140

EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 141

MorphoSys Enters into Licensing Agreement with Merck Serono 142

Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 143

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 144

ObsEva Enters Into Licensing Agreement With Merck Serono 145

Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 146

Merck Enters into Licensing Agreement with Weizmann Institute of Science 147

Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 148

Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 149

EMD Serono Enters into Licensing Agreement with Sutro Biopharma 150

Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 151

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 152

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 153

Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 155

Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 156

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 157

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 158

EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 159

Materia Extends Licensing Agreement With Sigma Aldrich 160

PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 161

Ligand Pharma Enters Into Licencing Agreement With Merck 162

Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 163

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 164

Sigma Life Science Enters Into Licensing Agreement With Kyoto University 165

Equity Offering 166

KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 166

iOnctura Spin Out from Merck and Cancer Research Technology 167

Debt Offering 168

Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 168

Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 169

Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 170

Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 171

Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 172

Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 173

Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 174

Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 175

Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 176

Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 177

Asset Transactions 178

Procter & Gamble Receives Approval to Acquire 51.8% Stake in Consumer Health Business from Merck for USD4.2 Billion 178

Fresenius Acquires Biosimilars Business from Merck for USD703 Million 180

Zydus Healthcare Acquires Six Brands from Merck 181

Martin Dow Acquires Merck Operations in Pakistan 182

Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 183

Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 185

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 186

Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 187

Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 188

Acquisition 189

Merck Sante Sells 4.74% Stake in Poxel 189

Merck to Acquire Natrix Separations 190

Merck Sells Bangalore Genei for USD1.5 Million 191

Merck Acquires Sigma-Aldrich for USD17 Billion 192

Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 194

Merck And BASF Acquire Majority Stake In Innovation Lab 195

Albany Molecular Research Acquires Cedarburg Pharmaceuticals 196

EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 198

Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 199

Proxy Labs Acquires MicroSafe Laboratories From Millipore 200

Merck KGaA - Key Competitors 201

Merck KGaA - Key Employees 202

Merck KGaA - Locations And Subsidiaries 203

Head Office 203

Other Locations & Subsidiaries 203

Recent Developments 213

Strategy And Business Planning 213

Oct 17, 2018: Merck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt 213

Jun 05, 2018: Merck Brings Biotechs Closer to Drug Therapy Production and Commercialization 214

Oct 11, 2017: Merck Opens New Life Science Center for Scientific Collaboration 215

Oct 11, 2017: MilliporeSigma Opens New Life Science Center in Massachusetts for Scientific Collaboration 216

Sep 28, 2017: Merck On Course To Achieve Objectives for 2018 217

Sep 22, 2017: Merck Opens China's First BioReliance End-to-End Biodevelopment Center in Shanghai 219

Sep 13, 2017: Merck Expands Celonic's Upstream Capabilities with Mobius Single-use Bioreactors 220

Sep 05, 2017: Merck Prepares Strategic Options for the Consumer Health Business 221

Jun 29, 2017: Merck Expands Packaging Capacity at Swiss Biotech Manufacturing Site of Aubonne 222

Jun 20, 2017: Merck Ventures Creates New Immuno-Oncology Company iOnctura 223

May 16, 2017: Merck: Optimizing the Further Development of the Darmstadt Site 224

May 12, 2017: Merck Opens First Joint Bioprocess Scale-up Lab with Stelis Biopharma in India 225

Apr 20, 2017: Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius Bioreactors 226

Jan 10, 2017: Merck Expands End-to-End Biodevelopment Centers in North America, China and Europe 227

Financial Announcements 228

Feb 02, 2018: Merck Announces Fourth-Quarter and Full-Year 2017 Financial Results 228

Nov 09, 2017: Merck Confirms Outlook for 2017 Despite a Challenging Third Quarter 233

Aug 03, 2017: Q2 2017: Merck Sets Course for Future Growth 235

May 18, 2017: Merck Continues to Grow Profitably in the First Quarter 237

Corporate Communications 239

Jan 26, 2018: Merck Appoints Dirk Toepfer as Chief Information Officer 239

Dec 15, 2017: Petra Wicklandt Appointed Head of Corporate Affairs at Merck 240

Dec 12, 2017: Allan Gabor Takes Over the Leadership of Merck in China 241

Dec 06, 2017: Merck: Resignation of Managing Director 242

Aug 03, 2017: Executive Board Changes at Merck 243

Legal and Regulatory 244

Feb 23, 2018: Fish & Richardson Wipes Out $2.5 Billion Patent Verdict Against Gilead Sciences on JMOL 244

Apr 19, 2017: Merck Earns Accreditation for Quality Control of Culture Media 245

Government and Public Interest 246

Jun 12, 2018: Merck Drives Thought Leadership in Ethical Gene Editing 246

Mar 19, 2018: The Pistoia Alliance Calls for Greater Life Sciences Collaboration to Build the Lab of the Future' 247

Nov 10, 2017: Merck Announced as 2017 "Simply the Best Award" Honoree at the Bonnie J. Addario Lung Cancer Foundation's "Simply the Best" Dinner and Gala 248

Oct 26, 2017: Merck Announces Recipients of 1 Million Grant for Multiple Sclerosis Innovation at ECTRIMS 2017 249

Sep 18, 2017: Merck Announces Recipients of the Grant for Growth Innovation 2017 250

Sep 10, 2017: Merck Grant for Oncology Innovation' awards recognize recipients for pushing boundaries in oncology research 251

Jul 06, 2017: Merck Biopharma Innovation Cup 2017 252

Jul 05, 2017: Merck Awards 1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation 253

Jul 05, 2017: Merck KGaA, Darmstadt, Germany Awards 1.25 Million to Research Projects Through its 2017 Grant for Fertility Innovation 254

Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 255

Product News 256

Nov 13, 2017: Merck Introduces Stericup Quick Release System for Improved Cell Culture Filtration 256

Oct 30, 2017: Merck: Product Announcement: Process Solutions 257

10/20/2017: Merck Presents New Clinical Data on Evobrutinib at 2017 ACR/ARHP Annual Meeting 258

10/18/2017: Merck to Present New Data on Evobrutinib at ECTRIMS 2017 260

Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 262

Sep 20, 2017: Merck Introduces Eshmuno P Anti-A and Anti-B Chromatography Resins for Enhancement of Plasma-Derived Immunoglobulin 264

06/23/2017: Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis 265

Jun 08, 2017: BioMed X and Merck launch two new crowdsourcing projects in the fields of cancer research and biologics manufacturing 266

05/22/2017: Novel Nanobody To Start Clinical Development In Osteoarthritis Ablynx To Receive 15 Million Milestone Payment 267

May 17, 2017: Merck Develops Alternative CRISPR Genome Editing Method 268

May 15, 2017: Merck Launches Industry's First Off-the-Shelf Cell Culture Media for Perfusion Processes 269

04/28/2017: Investigational Cladribine Tablets Data Show Greater Treatment Effect in Relapsing MS Patients at a Higher Risk of Disease Progression 270

Apr 27, 2018: Merck Advances Cell Analysis with New Benchtop Flow Cytometer with Camera Detection 271

04/21/2017: Merck to Present Data on Cladribine at AAN 2017 272

Apr 03, 2017: Merck Wins Scotland's Life Science Award for Excellence in Community Engagement 275

Mar 06, 2017: Merck Advances Lab Water Purification Technology with Milli-Q(R) IQ 7000 System 276

Feb 13, 2018: Merck Launches Viresolve Barrier Capsule Filters to Protect Against Bioreactor Contamination 277

Clinical Trials 278

Jun 04, 2018: Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018 278

May 16, 2018: Merck to Present M7824 Data at ASCO 2018 280

Apr 17, 2018: Merck to Present Data for Osteoarthritis Drug Candidate M1673 at OARSI 2018 World Congress 281

Apr 17, 2018: Merck to Present Data on its ADAMTS-5 inhibiting nanobody M6495 at OARSI 2018 World Congress 283

Apr 17, 2018: Merck to Present on Sprifermin at OARSI 2018 World Congress 285

Jan 16, 2018: Merck Presents Data on Bifunctional Immunotherapy M7824 at ASCO 2018 Gastrointestinal Cancers Symposium 287

Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification 289

Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting 290

Sep 12, 2017: Merck Advances Immunology Pipeline with Evobrutinib (Brutons Tyrosine Kinase Inhibitor) 292

Jun 26, 2017: Data Provide Additional Insight into the Mode of Action of MAVENCLAD (Cladribine Tablets) in Patients with Relapsing MS 293

Feb 09, 2017: Cladribine Tablets Significantly Reduced Brain Atrophy in Patients with Multiple Sclerosis 294

Other Significant Developments 295

Aug 06, 2018: Merck Foundation Continues to Strengthen Their Merck Cancer Access Program in Gambia, Lesotho, Botswana and Zimbabwe 295

Feb 21, 2018: Merck Invests Additional 40 Million to Enhance Manufacturing and Distribution in Asia 296

Dec 11, 2017: Merck Signs Distribution Agreement with Avanti Polar Lipids 297

Oct 03, 2017: Merck Invests 35 Million in its Italian Biotech Manufacturing Site of Bari 298

Sep 27, 2017: Merck Provides Update on EU's Horizon 2020 Program to Improve Biopharmaceutical Downstream Processing 299

Jul 12, 2017: Merck Refines Western European Life Science Production Site Network 300

Mar 21, 2017: Merck Introduces Mobius MyWay Portfolio for Customized Single-Use Assemblies 301

Mar 21, 2017: Merck Accelerator Hits New Peak of Applications 302

Mar 09, 2017: Merck Generates Record Sales and Continues to Grow Profitably in 2016 303

Feb 15, 2017: Merck to Supply Single-use Systems to WuXi Biologics for Non-GMP Pilot Plant in Shanghai 305

Jan 18, 2017: Merck Launches First Commercial Screening Service to Predict Multiple Sources of DNA Damage 306

Appendix 307

Methodology 307

About GlobalData 307

Contact Us 307

Disclaimer 307


List Of Figure

List of Figures

Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 16

Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18


List Of Table

List of Tables

Merck KGaA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 13

Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 15

Merck KGaA, Deals By Therapy Area, 2012 to YTD 2018 16

Merck KGaA, Medical Devices Deals, 2012 to YTD 2018 18

Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 19

Merck KgaA Acquires SevenSeas Original Brand 28

Sutro Biopharma Raises USD85.4 Million in Series E Financing 29

SerImmune Raises USD8 Million in Venture Financing 31

TocopheRx Raises USD 3.3 Million In Seed Financing 32

Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 33

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 34

Accelerated Cure Project Enters into Co-Development Agreement with EMD Serono 35

Immutep Enters into Agreement with Merck and Pfizer 36

Checkmate Pharma Enters into Partnership with Merck and Pfizer 37

Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 38

Vyriad Enters into Collaboration Agreement with Merck and Pfizer 39

Merck Enters into Co-Development Agreement with Xian-Janssen Pharma 40

Merck Enters into Development Agreement with SFJ Pharma 41

Forty Seven Enters into Agreement with Merck 42

Merck Enters into Agreement with Avanti Lipids Polar 43

Neon Therapeutics Enters into Agreement with Merck 44

Orexigen Therapeutics Enters into Agreement with Merck KGaA 45

MilliporeSigma to Enter into Agreement with Samsung Biologics 46

Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 47

MilliporeSigma Enters into Agreement with Angiex 48

Merck Enters into Partnership with Angiex 49

Millipore Enter into Partnership with Baylor College of Medicine and Texas Children's Hospital 50

Acino International Enters into Distribution Agreement with Merck 51

Cancer Research Technology Enters into Agreement with Merck 52

eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 53

SerImmune Enters into R&D Agreement with Merck 54

Human Longevity Enters into Agreement with Merck 55

F-star Biotech Enters into Partnership with Merck 56

EpiThany Enters into Agreement with Merck and Pfizer 57

VAXIMM Enters into Agreement with Merck and Pfizer 58

Avillion Enters into Co-Development Agreement with Merck 59

Merck Enters into Agreement with Palantir Technologies 60

EMD Serono Enters into Agreement with University of Texas MD Anderson Cancer Center 61

F. Hoffmann-La Roche Expands its Distribution Agreement with MilliporeSigma 62

Evotec Partners with Merck 63

BioMed X Enters into Agreement with Merck 64

Debiopharm Partners with Merck and Pfizer 65

Transgene Enters into Agreement with Merck and Pfizer 66

Vaccinex Enters into Agreement with Merck 67

PCAS Enters into Distribution Agreement with MilliporeSigma 68

MilliporeSigma Enters into Research Agreement with International Vaccine Institute 69

Selvita Enters into Agreement with Merck 70

Merck Enters into Agreement with University of Buea 71

Merck, Pfizer and Verastem Enter into Agreement 72

Merck Enters into Research Agreement with European Molecular Biology Labs 73

Merck, Pfizer and Syndax Pharma Enter into Agreement 74

Selvita Enters into Development and Commercialization Agreement with Merck 75

Biothera Pharma Expands Agreement with Merck 76

Sigma-Aldrich Enters into Agreement with Sanger Institute 77

Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 78

Nippon Shinyaku Enters into Co-Promotion Agreement with Merck Serono 79

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 80

Aeterna Zentaris Enters into Agreement with EMD Serono 81

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 82

Lucigen Enters into Distribution Agreement with Sigma-Aldrich 83

Merck Serono Enters into Co-Development Agreement with MMV 84

Sigma-Aldrich Enters into Distribution Agreement with Roche 85

Merck Enters into Development Agreement with Precision Biologics 86

Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 87

Pfizer Enters into Co-Development Agreement with Merck 88

BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 90

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 91

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 92

Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 93

Lupin Enters into Co-Development Agreement with Merck Serono 94

Merck Serono Extends R&D Agreement with San Raffaele 95

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 96

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 97

Bionovis Enters into Agreement with Merck 98

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 99

EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 100

KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 101

Biopharm Enters Into Research Agreement With Merck Serono 102

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 103

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 104

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 105

Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 106

Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 107

Isu Abxis Enters into Co-Development Agreement with Merck 108

Luminex Extends Distribution Agreement With EMD Millipore 109

Alchemia Enters Into Collaboration Agreement with Merck Serono 110

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 111

Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 112

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 113

Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 114

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 115

EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 116

AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 117

EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 118

Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 119

Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 120

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 121

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 122

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 124

Genovis Enters Into Distribution Agreement With Sigma-Aldrich 125

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 126

EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 127

EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 128

Mapi Pharma Amends Co-Development Agreement With Merck 129

TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 130

Isotopen Enters into Option Agreement to License for Folate Receptor with Merck 131

Merck Enters into Licensing Agreement with Nerviano Medical Sciences 132

Selexis Enters into Licensing Agreement with Merck KGaA 133

Merck Enters into Licensing Agreement with Domain Therapeutics 134

Merck Enters into Licensing Agreement with Vertex Pharma 135

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 136

ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 137

EMD Millipore Enters into Licensing Agreement with Singulex 138

Intrexon Enters into Licensing Agreement with Merck Serono 139

Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 140

EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 141

MorphoSys Enters into Licensing Agreement with Merck Serono 142

Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 143

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 144

ObsEva Enters Into Licensing Agreement With Merck Serono 145

Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 146

Merck Enters into Licensing Agreement with Weizmann Institute of Science 147

Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 148

Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 149

EMD Serono Enters into Licensing Agreement with Sutro Biopharma 150

Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 151

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 152

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 153

Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 155

Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 156

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 157

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 158

EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 159

Materia Extends Licensing Agreement With Sigma Aldrich 160

PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 161

Ligand Pharma Enters Into Licencing Agreement With Merck 162

Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 163

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 164

Sigma Life Science Enters Into Licensing Agreement With Kyoto University 165

KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 166

iOnctura Spin Out from Merck and Cancer Research Technology 167

Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 168

Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 169

Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 170

Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 171

Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 172

Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 173

Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 174

Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 175

Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 176

Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 177

Procter & Gamble Receives Approval to Acquire 51.8% Stake in Consumer Health Business from Merck for USD4.2 Billion 178

Fresenius Acquires Biosimilars Business from Merck for USD703 Million 180

Zydus Healthcare Acquires Six Brands from Merck 181

Martin Dow Acquires Merck Operations in Pakistan 182

Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 183

Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 185

Eurofins Scientific Acquires Assets of Discovery and Development Solutions Business of Merck 186

Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 187

Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 188

Merck Sante Sells 4.74% Stake in Poxel 189

Merck to Acquire Natrix Separations 190

Merck Sells Bangalore Genei for USD1.5 Million 191

Merck Acquires Sigma-Aldrich for USD17 Billion 192

Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 194

Merck And BASF Acquire Majority Stake In Innovation Lab 195

Albany Molecular Research Acquires Cedarburg Pharmaceuticals 196

EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 198

Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 199

Proxy Labs Acquires MicroSafe Laboratories From Millipore 200

Merck KGaA, Key Competitors 201

Merck KGaA, Key Employees 202

Merck KGaA, Subsidiaries 203

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Merck KGaA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.